Novartis plans to focus on anti-TB pie
Pharma major Novartis India is planning to focus on the anti-TB segment in India. The company will source rifampicin from subsidiary Ciba-CKD Biochem's plant for the production of anti-TB
Pharma major Novartis India is planning to focus on the anti-TB segment in India. The company will source rifampicin from subsidiary Ciba-CKD Biochem's plant for the production of anti-TB